These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39096666)

  • 21. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
    Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
    Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
    Front Immunol; 2021; 12():614715. PubMed ID: 33841397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Koch M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):391. PubMed ID: 37963724
    [No Abstract]   [Full Text] [Related]  

  • 25. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 26. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
    Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    Chisari CG; Grimaldi LM; Salemi G; Ragonese P; Iaffaldano P; Bonavita S; Sparaco M; Rovaris M; D'Arma A; Lugaresi A; Ferrò MT; Grossi P; Di Sapio A; Cocco E; Granella F; Curti E; Lepore V; Trojano M; Patti F;
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1297-1303. PubMed ID: 33055141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Trojano M; Ramió-Torrentà L; Grimaldi LM; Lubetzki C; Schippling S; Evans KC; Ren Z; Muralidharan KK; Licata S; Gafson AR
    Mult Scler; 2021 Dec; 27(14):2240-2253. PubMed ID: 33821693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration.
    Page LJ; Pay IF; Castellana ET; Heussen R; Hoyt T; Foley J; Messmer BT
    Mult Scler Relat Disord; 2024 Jul; 87():105667. PubMed ID: 38759421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    Filippi M; Grimaldi L; Conte A; Totaro R; Valente MR; Malucchi S; Granella F; Cordioli C; Brescia Morra V; Zanetta C; Perini D; Santoni L;
    J Neurol; 2024 Jan; 271(1):340-354. PubMed ID: 37715789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfer of natalizumab into breast milk in a mother with multiple sclerosis.
    Baker TE; Cooper SD; Kessler L; Hale TW
    J Hum Lact; 2015 May; 31(2):233-6. PubMed ID: 25586712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab.
    van Rossum JA; van Kempen ZLE; Schilder L; Lissenberg-Witte BI; Uitdehaag B; Killestein J
    Mult Scler Relat Disord; 2019 Nov; 36():101382. PubMed ID: 31546224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
    Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
    Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
    [No Abstract]   [Full Text] [Related]  

  • 40. Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route.
    López PA; Alonso R; Silva B; Carnero Contentti E
    Mult Scler Relat Disord; 2021 Oct; 55():103179. PubMed ID: 34339931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.